Description
OVERVIEWProduct overview
Crystagen belongs to the family of short synthetic peptide bioregulators described predominantly in Russian gerontology and immunology literature.
Published work in this family concerns gene expression, cell differentiation and immune parameters in cell and animal models.
The evidence base is narrow and largely single-region. The compound is supplied for laboratory research only.
SUPPLY IN IRELANDCrystagen Ireland — supplied to research laboratories
Research groups across Ireland buy Crystagen from Kensington Laboratories as a lyophilised Crystagen peptide, released only against a batch-matched certificate of analysis. Every vial of high purity Crystagen is verified by HPLC and LC-MS before it leaves the facility, so laboratories ordering Crystagen in Ireland receive material with documented purity and identity.
Laboratory Crystagen is packed for controlled storage and sent by tracked delivery in 3–5 days to Dublin, Cork, Galway, Limerick and the rest of Ireland. Delivery costs €9.90 per order. Teams planning Crystagen research can review the specifications, certificate of analysis and reference list on this page before ordering.
Institutions searching for Crystagen peptide suppliers in Ireland typically compare purity, batch documentation and delivery times. Each of those is published here: a 99% HPLC purity specification, a certificate matched to the batch code on your vial, and tracked delivery in 3–5 days.
Crystagen is supplied strictly for laboratory research use only. It is not a medicine and is not for human or veterinary consumption.
SPECIFICATIONSProduct specifications
- Purity: ≥ 99% (HPLC)
- Appearance: White lyophilised powder
- Quantity: 20 mg per vial
- Peptide class: Short synthetic peptide bioregulator
- Also known as: Peptide bioregulator, Glu-Asp-Pro derived tetrapeptide
- Solubility: Soluble in bacteriostatic or sterile water
- Storage temperature: Store at 2–8°C; long-term −20°C, protected from light
- Shelf life: 24 months lyophilised; 30 days reconstituted at 2–8°C
- Manufacturing standard: ISO 9001 facility, GMP-aligned solid-phase synthesis
- Batch information: Batch number and expiry printed on every vial label
RESEARCHResearch overview
The following summary is provided for educational and scientific context only. It describes what has been observed in published laboratory and animal studies and does not represent established clinical outcomes, medical advice or a claim of efficacy in humans.
Background
Crystagen belongs to the family of short synthetic peptide bioregulators described predominantly in Russian gerontology and immunology literature.
Published work in this family concerns gene expression, cell differentiation and immune parameters in cell and animal models.
The evidence base is narrow and largely single-region. The compound is supplied for laboratory research only.
Current research areas
Published investigation clusters around a small number of biological themes. Each remains experimental and none has been established as a therapeutic effect in humans.
- Peptide bioregulator research
- Immune parameter measurement in animal models
- Gene expression and differentiation studies
- Comparative work across the bioregulator family
Scientific context and proposed mechanisms
Authors in this field propose direct interaction of short peptides with DNA and regulation of gene expression, a mechanism that has not been widely reproduced outside the originating groups.
Independent replication is limited and findings should be treated as preliminary.
Interpreting the evidence
Most published work in this area uses cell culture or rodent models with small group sizes and short observation windows. Independent replication varies considerably between compounds, and results are sensitive to species, route, dose and endpoint.
There is no regulatory-approved human protocol for this compound. Any laboratory protocol should be defined by the model under study, institutional ethical approval, appropriate controls and predefined endpoints.
References
CERTIFICATE OF ANALYSISIndependent batch testing
Every released batch is independently tested. Match the batch number on the vial to the certificate published online.
- Batch number
- KL-CRYSTAGEN-2407A
- Testing laboratory
- Janoshik Analytical, s.r.o.
- Date tested
- 2 July 2026
- Reported purity
- 99.42%
- Method
- RP-HPLC with UV detection at 214 nm, confirmed by LC-MS
The independent result for this batch is summarised above. Contact the laboratory team if you need the full report for this batch.
